ERJ open research
THE BEST IN OPEN ACCESS BASIC, TRANSLATIONAL & CLINICAL RESPIRATORY RESEARCH

Early View

Original article

Endobronchial autologous bone marrow-mesenchymal stromal cells in idiopathic pulmonary fibrosis (phase I)

Arantza Campo, José María González-Ruiz, Enrique Andreu, Ana B. Alcaide, María M. Ocón, Juan De-Torres, Jesús Pueyo, Rosa Cordovilla, Eva Villaron, Fermín Sanchez-Guijo, Miguel Barrueco, Jorge Nuñez-Córdoba, Felipe Prósper, Javier J. Zulueta

Please cite this article as: Campo A, González-Ruiz Jé Mía, Andreu E, *et al*. Endobronchial autologous bone marrow-mesenchymal stromal cells in idiopathic pulmonary fibrosis (phase I). *ERJ Open Res* 2021; in press (https://doi.org/10.1183/23120541.00773-2020).

Endobronchial autologous bone marrow-mesenchymal stromal cells in idiopathic pulmonary fibrosis (phase I)

Authors

Arantza Campo, MD (1)*, José María González-Ruiz, MD (2), Enrique Andreu, PhD (3), Ana B. Alcaide, MD (1), María M. Ocón (1), Juan De-Torres, MD (1), Jesús Pueyo, MD (4), Rosa Cordovilla, MD (2), Eva Villaron, PhD (5), Fermín Sanchez-Guijo, MD (5), Miguel Barrueco, MD (2), Jorge Nuñez-Córdoba, MD (6), Felipe Prósper, MD (3)#, Javier J. Zulueta, MD (1)#

#Both authors share last authorship

(1) Clínica Universidad de Navarra, Pulmonary Medicine; (2) Hospital Universitario de Salamanca, Pulmonary Medicine; (3) Clínica Universidad de Navarra, Hematology – Cell therapy area; (4) Clínica Universidad de Navarra, Radiology Department; (5) Hospital Universitario de Salamanca, Hematology; (6) Clínica Universidad de Navarra. Division of Biostatistics, Research Support Service, Central Clinical Trials Unit

*__Corresponding author__: Arantza Campo, MD. Servicio de Neumología. Clínica Universidad de Navarra. Pamplona, Spain. Email acampoe@unav.es

Contributions: Conception and design: AC, JMGR, EA, ABA, JDT, JP, RC, EV, FSG, MB, FP, JZ; Acquisition of data: AC, JMGR, EA, ABA, JDT, JP, RC, MMO, JZ; Analysis and interpretation: AC, EA, MMO, JNC, FP, JZ; Drafting the manuscript: AC, EA, FP, JZ; Revising it critically for valuable intellectual content: AC, EA, FP, JZ.

Source of support: This clinical trial has been supported by the Spanish Ministry of Health, Social Policy, and Equality (EC11-064)

Running head: Endobronchial autologous BM-MSCs in IPF patients

Abstract

Rationale: Idiopathic pulmonary fibrosis (IPF) has a dismal prognosis. Mesenchymal stromal cells have shown benefit in other inflammatory diseases.

Objectives: Evaluate the safety and feasibility of endobronchial administration of bone marrow autologous MSCs (BM-MSC) in patients with mild-to-moderate IPF.

Methods: A phase-I multicenter clinical Trial (ClinicalTrials.gov:NCT01919827) with a single endobronchial administration of autologous adult BM-MSC in patients diagnosed with mild-to-moderate IPF. In a first escalating-dose phase, 3 patients will be included sequentially in 3 dose cohorts (10x10^6, 50x10^6, and 100x10^6 cells). In a second phase, 9 patients will receive the highest tolerated dose. Follow-up with PFT, 6MWT, and SGRQ were done at 1, 2, 3, 6, and 12 months, and with a computed tomography at 3, 6, and 12 months.

Findings: Twenty-one bone marrow samples were obtained from 17 patients. Three patients were excluded for treatment due to chromosome aberrations detected in MSCs after culture, and one patient died before treatment. Finally, 13 patients received the BM-MSCs infusion. No treatment related severe adverse events were observed during follow-up. Compared to baseline, the mean FVC showed an initial decline of 8.1% at three months. The number of patients without functional progression was 6 (46%) at 3 months and 3 (23%) at 12 months. **Conclusions**: The endobronchial infusion of BM-MSCs did not cause immediate serious adverse events in IPF patients, but a relevant proportion of patients suffered clinical and/or functional progression. Genomic instability of BM-MSCs during culture found in three patients may be troublesome for the use of autologous MSCs in IPF patients.

Keywords: interstitial lung disease, cell therapy, idiopathic pulmonary fibrosis

Introduction

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease characterised by progressive fibrosis, loss of pulmonary function, and high mortality with an average survival from the time of diagnosis of 2 to 5 years. It is the most common and severe form of idiopathic interstitial pneumonias. Aetiology involves genetic susceptibility(1),(2),(3) exposure factors, and autoimmunity, leading to complex mechanisms such as cell senescence, impairment of repair mechanisms and host defence, and bronchoalveolar epithelial dysfunction(4).

Identification of new targets may allow the development of new drugs for this condition(5). New commercialised drug treatments in last few years such as pirfenidone and nintedanib may slow the progression of the disease(6),(7),(8),(9),(10),(11), reduce exacerbations(12),(13),and improve survival(14). However, prognosis remains poor(15),(16),(17), and treatments that can cure or definitively halt the disease are still lacking.

Cell therapies have been proposed as a possible therapy for IPF. Immune modulatory effects of mesenchymal stromal cells(18),(19) have been proven to be beneficial and safe in laboratory conditions. Studies animal models of lung injury, or bleomycin-driven fibrosis, showed attenuation of fibrosis and reduced inflammation (20),(19),(21),(22),(23),(24). MSCs can be obtained from different sources (bone-marrow, adipose tissue, umbilical cord, placenta, dental pulp, menstrual blood, or lung, among others) and expanded by culture. In the lung, MSCs engraft for a short period of time although may engraft for longer periods in damaged lungs (24) (25). The therapeutic effect observed in different conditions is mediated mainly through paracrine mechanisms. Immunomodulation is mediated through interaction with other cells within the innate and adaptive immune systems, paracrine actions with release of soluble mediators, release of extracellular vesicles, or by transfer of organelles such as mitochondria (26).

Three phase 1b-clinical trials using adult MSCs have been conducted in IPF patients. The origin and type of cells and the route of administration differ, namely autologous adipose derived MSCs by endobronchial infusion in 14 patients(27), intravenous administered placenta-derived MSCs in 8 patients(28), and intravenous allogeneic MSCs in 9 patients(29). None of the three studies reported any serious adverse events (AEs) at follow-up between 6 and 12 months. One study with a longer follow-up reported lung function decline during the subsequent two years (30).

The benefits, best source of the MSCs (autologous vs allogeneic), their origin, route of delivery (intravenous, endobronchial/endotracheal, or even aerosolised), and dosing remain questioned for lung diseases, including IPF. MSCs originated from different sources might contain different secretome properties. Bone marrow-derived MSCs might have shown superior immunomodulatory effects compared to cells obtained from other sources(31). Endobronchial infusion might also confer an advantage regarding homing and retention of the cells in the lungs.

This study aimed to evaluate the safety and feasibility of the endobronchial administration of mesenchymal autologous stromal cells derived from bone marrow in patients with mild-to-moderate idiopathic pulmonary fibrosis.

Methods

Subjects and study design

This study was a phase I clinical trial of a single endobronchial administration of adult BM-MSC in patients diagnosed with IPF, recruited between 2013 and 2016 and followed for 12 months. The centres for recruitment, MSCs production, and treatment were Clínica Universidad de Navarra (Pamplona, Spain) and IBSAL-Hospital Universitario de Salamanca (Salamanca, Spain). The estimated number of patients to be included was 18.

The protocol and all the procedures were approved by the Navarra Ethics Committee for Clinical Trials with Human Subjects (CEIC Navarra 01/2012) and by the Spanish Agency for Medicines and Health Products (AEMPS) (Nº EudraCT: 2011-006240-75, ClinicalTrials.gov: NCT01919827). All patients provided written informed consent.

Criteria for eligibility of patients

Inclusion criteria: 1) males or females aged 30-80 years, 2) diagnosed with definite or probable IPF by high resolution computed tomography (HRCT) and/or biopsy, according to ATS 2011 criteria (32) and after the exclusion of other known causes by history, examination, complementary blood tests, and multidisciplinary discussion (MDD), 3) mild-moderate IPF defined by pulmonary function tests (functional vital capacity (FVC %predicted) ≥50% and diffusing lung capacity (DLCO %predicted) ≥35%), and 4) able to perform a 6-minute walk test (6MWT), and to fulfil all the requirements of the study protocol at the time of inclusion.

Exclusion criteria were current pregnancy or lactation, significant emphysema or any obstructive or restrictive respiratory conditions other than IPF, hospitalisation or active respiratory infection within 60 days before inclusion, frequent exacerbations of IPF (>2 episodes/year over the last two years), chronic severe heart or renal failure, previous neoplasm within five years, active treatment (pirfenidone, nintedanib, immunosuppressant or corticosteroids >10 mg prednisone), any medical or psychiatric condition that may limit life expectancy or interfere with the treatment of the study, and positive tests for HIV, HBsAg, HCV antibody, or syphilis screening assays.

Treatment groups

Patients enrolled were sequentially assigned to 3 groups with escalating doses: low ($10x10^6$ cells), intermediate ($50x10^6$ cells), and high ($100x10^6$ cells) dose. The study followed two phases: in phase I, 3 patients were included in each of the 3 dosing groups for a total of 9 patients. Before escalating to the next dose, the 3 patients had to complete 3 months of

follow-up without severe adverse events (AE). In a second phase, 9 patients received the highest tolerated dose.

Cell culture and infusion

BM-MSCs were generated under good manufacturing practice conditions (GMP) with standard operating procedures, as previously described(33). Bone marrow (100 ml) was harvested from the pelvic bone (iliac crest) under sterile conditions. The mononuclear cell fraction was isolated by Ficoll density gradient centrifugation (Ficoll-Paque, GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Cells, ranging between 20 $x10^6$ and 60 $x10^6$, were subsequently seeded in 175 cm^2 flasks with a growth medium, which consisted of αMEM without ribonucleosides (Gibco, Life Technologies, Carlsbad, CA, USA) supplemented with 5 % platelet lysate, 2 units/ml heparin, penicillin-streptomycin at 1 % (Gibco) and 1 ng/ml human fibroblast growth factor (bFGF) (Sigma-Aldrich, St. Louis, MO, USA). The flasks were maintained in culture at 37 °C in a 5 % CO2 atmosphere. The growth medium was changed every 3–4 days. About 10–15 days later, once colonies formed, the cells were split with TrypLE Select™ (Life Technologies) and seeded at 3000– 5000 cells/cm^2. Once 70–80 % confluence was reached, cells were split again and cultured until they were available at the amounts required. Finally, cells were harvested with TrypLE Select™, washed three times with PBS, and re-suspended in Ringer's lactate buffer (Grifols, Barcelona, Spain) containing 1 % human albumin (Grifols), for administration within 24 h of harvesting of the cells. Cells were characterized according to ISCT criteria. Cells were then analysed by flow cytometry (FACSCalibur, BD Biosciences, San José, CA, USA) with the appropriate antibodies (BD Biosciences) to confirm the expression of surface markers CD90, CD73 and CD44, as well as the absence of CD34 and CD45. Genetic stability was assessed by Array Comparative Genomic Hybridisation (CGH) (NIM Genetics). Serial microbiological controls were performed along the MSCs expansion and before the infusion.

Once appropriateness was confirmed, MSCs were diluted in Ringer Lactate with human albumin 1% and divided into 4 aliquots for administration. Under conscious sedation, a flexible bronchoscope was inserted and advanced to one of the lower lobes. MSCs were infused by a telescoping protected catheter (Combicath®, Prodimed) in 4 different segments of one of the lungs, followed by an infusion of 2 mL of saline. The total amount of fluid ranged from 20 mL to 50 mL for the different doses. Unilateral infusion was performed to avoid a large amount of fluid into the lungs, keep one of the lungs preserved, and allow future comparison. As a general rule, the lung with less fibrotic changes was selected for the infusion.

Follow-up assessment and outcomes of interest

The study's primary objective was to evaluate the safety and feasibility of the endobronchial administration of mesenchymal autologous stromal cells derived from bone marrow (BM-MSCs) in patients with mild-to-moderate idiopathic pulmonary fibrosis. A secondary objective was to assess the disease's course as a possible effect of BM-MSCs infusion in slowing or stopping the decline in pulmonary function.

Patients were followed-up at 1, 2, 3, 6, 9, and 12 months after treatment. All the follow-up visits included pulmonary function tests (PFTs), 6-minute-walk-test (6MWT), dyspnoea and cough questionnaires, Saint George Respiratory Questionnaire (SGRQ), and blood analysis. PFTs included spirometry, lung volumes, and diffusing capacity (Vmax 22; Sensormedics Corp; Yorba Linda (California), following American Thoracic Society recommendations. Values are expressed as percent of predicted reference values (%predicted). HRCT was done at 3, 6, and 12 months.

Primary safety endpoints were the incidence and severity of adverse events during follow-up for up to 12 months. Adverse events are named using the Medical Dictionary for Regulatory Activities (MedDRA) version 22.0. The severity of AEs was graded as mild, moderate, severe,

and life-threatening, according to clinical intensity, impact on usual activities, and need for medical care.

A serious adverse event (SAE) was defined by any medical occurrence that resulted in death, was life-threatening, required inpatient hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect.

Efficacy endpoints were: 1) change in forced vital capacity (FVC) as a continuous variable and 2) progression of the disease defined by death, need for transplantation, or deterioration in pulmonary function defined by fall in FVC ≥ 10% or lung diffusion capacity (DLCO) ≥ 15%.

Statistics

Quantitative variables were summarized using means with standard deviations (SD) or median (IQR) and categorical data with frequencies and percentages. The Shapiro-Wilk test checked the assumption of normality. Values at the follow-up visits were compared with baseline levels using paired t-tests or Wilcoxon matched-pairs signed-ranks tests. Two-tailed p values < 0.05 were considered statistically significant. All analyses were performed with Stata 14 (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP).

Results

Demographics of patients

Eighteen patients were assessed for eligibility from April 2013 to December 2016. One patient was determined to be a screening failure since results of the first PFTs did not meet inclusion criteria.

The diagram in Figure 1 shows the patients initially screened, those excluded, and the patients who received treatment. In summary, 21 bone marrow samples were obtained from 17 patients (15 males, 2 females). Seven expanded cultures from 4 patients resulted in non-appropriate cells (3 had mosaic trisomy in chromosome 5, and 1 did not have viable cells), and were discarded for treatment. A second attempt conducted in these 4 patients obtained trisomy in chromosome 5 in 3 cases (75%). For those individuals with trisomies in the BM-derived-stromal cells after culture, bone marrow cells prior to culture were studied using CGH array and confirmed to be normal. One patient died unexpectedly before treatment. Finally, 13 patients received MSCs at the corresponding dose.

The baseline characteristics of the 13 patients who received treatment are shown in Table 1. Patients were predominantly male (12/13), with a median age of 68 years (range of 54,4 to 79,5), and a history of smoking in 10 (76.9%). The median time since the onset of symptoms was 3.3 years (range of 0.5 - 7.8), and the median time since diagnosis was 1.2 years (range 0.2-8.1).

Diagnosis of IPF was based on HRCT features in 8 patients and on HRCT and lung biopsy in 5 patients. Underlying known causes or other diagnoses were discarded by history, examination and complementary tests, and multidisciplinary discussion (MDD). PFTs at baseline showed a mean FVC of 75.6%±20.3%predicted, TLC of 61.5±13.2%predicted, and DLCO of 46.9% ± 12.9%predicted. The six-minute walk test distance was 488 ± 69.2 m.

Safety

The median follow-up for the 13 patients was 10.1 months (IQR 6.8 - 12.9; range 2.2 to 13.6 months). Three patients died during the 12-months follow-up period because of progression of the underlying pulmonary fibrosis, *Legionella* pneumonia, and general progressive deterioration of unknown cause, respectively. One patient received lung transplantation at six

months due to the progression of the disease. Finally, ten patients completed follow-up at 6-months and six patients at 12-months.

Thirty adverse events (AE) were reported in 13 patients (Table 2). The severity of AEs was considered mild in 16 (53.3%), moderate in 10 (33.3%), severe in 3 (13.7%), and life-threatening in 1 (3.3%). The more frequent AE besides IPF progression were bronchitis (8 patients), upper tract infection (2), and flu-like symptoms (2). Fever and increase in dyspnoea within the first 24 hours after infusion not requiring hospitalisation occurred in 3 patients who had received the highest dose of MSCs ($100x10^6$).

AE were serious in four patients, leading to four hospitalisations in three patients and death in three. Besides IPF progression, two AE were fatal (Legionella infection and general deterioration). This last patient had weight loss, abdominal pain and a debilitating process; work-up was conducted with abdominal and thorax CT, GI tract endoscopy, and blood tests without evidence of neoplastic or infectious disorder. He continued clinical follow-up locally in another centre, and the final cause of death could not be determined.

One patient received bilateral lung transplantation at 6-months due to IPF progression, manifested mainly by exercise-induced hypoxia. The gross and microscopical examination of the explanted lungs reported diffuse and chronic interstitial pneumonia with honeycomb change in both lungs, without evidence of malignancy or other remarkable findings; final diagnosis was usual interstitial pneumonia. Evidence of engraftment or regeneration by administered cells was not found.

Two patients developed cancer during the follow-up period. One patient, 79 years-old, with previous bladder cancer six years before entry, was diagnosed with prostate cancer six months after MSCs infusion. Another patient, 61 years-old, former smoker, with a baseline 23x20 mm atypical consolidation in left lower lobe (LLL) not considered suspicious of malignancy, received MSCs in this LLL and developed a contralateral nodule in the right lower lobe (11 x 9 mm) at

three months, with subsequent growth at six months (17x14mm), without significant changes in the LLL. An FDG-PET study revealed abnormal metabolic activity in both lesions. A subsequent transthoracic biopsy of the new nodule demonstrated small cell lung cancer. The clinical interpretation was that he had a previous primary neoplasm in LLL and which metastasized to the contralateral lung. Chemotherapy and nintedanib were initiated after diagnosis. Even though the original lesion was present before MSCs treatment, any deleterious effect of the MSCs cannot be determined nor discarded. None of these serious AEs were considered directly related to the treatment.

Assessment of pulmonary function

As shown in Table 3,PFTs, six-minute walk tests, and SGRQ questionnaires were performed at every follow-up visit. Individual baseline FVC and DLCO values and changes during follow-up are shown in Table 4 and depicted in Figure 2.

All thirteen patients were revisited at three months and performed PFTs with a change in mean FVC of -212 ± 275 mL ($p<0.05$) and a change in FVC%predicted of -8.1% (p-value not significant.); there were no significant changes in DLCO and 6MWT distance. Six patients remained functionally stable with falls in FVC of less than 10% and in DLCO of less than 15%.

The number of patients followed-up at 6, 9, and 12 months was 10, 7, and 6 patients, respectively. Table 3 shows mean FVC and DLCO values and the number of patients with clinically significant declines. At the end of follow-up (12 months), three patients were stable in terms of pulmonary function considering both FVC and DLCO. The overall outcome at the last visit or follow-up contact was stability for three patients, functional decline for 6 patients, lung transplantation for one patient, death due to progression in one patient and death from other causes in two patients, as shown in Table 4.

Discussion

The main finding of this study is that infusion of MSCs into the lungs via bronchoscopy in patients with idiopathic pulmonary fibrosis results in a low incidence of directly attributable side effects, yet significant progression of the disease was observed. Three patients had early adverse events attributable to the infusion, namely fever and/or dyspnoea, not leading to hospitalisation or subsequent IPF exacerbation. All three were in the higher dose group and thus received a greater volume of infused fluid during the procedure. Other adverse events were unlikely related to the treatment, as they were not temporally correlated, although this cannot be ruled out entirely. Most AEs were common syndromes like bronchitis, flu-like syndrome, upper respiratory tract infections, and acute gastroenteritis, accounting for 45% of AEs.

Two patients had a diagnosis of cancer during the follow-up period. Although carcinogenesis has been a concern in any treatment with stromal cells, the nature and development of the tumours seen, and previous knowledge from other clinical trials in which no AEs related to malignancy were reported, make it unlikely that the cancers observed during this study were due to treatment with MSCs (25).

Clinical IPF progression was observed as an adverse event in 7 patients during the follow-up, causing 3 hospitalisations in 2 patients, lung transplantation in 1 patient, and death in one patient. Compared to baseline, median FVC declined significantly at three months. During follow-up, pulmonary function was stable in 6 patients at three months and only in 3 patients at 12 months. As shown in Table 4, patients with better outcomes had higher baseline pulmonary parameters, meaning that patients with mild disease are more stable and less prone to deterioration. Although IPF progression has hardly been reported in other clinical trials(27) (28), the AETHER study (29) showed that 2 out of 9 patients died due to IPF progression, a similar proportion than our study. Longitudinal outcomes obtained from a

previous phase I study with autologous adipose tissue driven MSCs (27) showed a median survival of 32 months, with 12 out of 14 patients dying due to disease progression(30).

The study was designed before the final approval of antifibrotic drugs in the European Union and Spain. During the trial, the availability and authorization of these drugs for the individual patients were diverse. Recommendations for therapy with of antifibrotics drugs (pirfenidone or nintedanib) were made in all pre-screened patients where, and when available. The recommendations were reiterated for recruited patients during the clinical follow-up, and especially if there was any deterioration. All this caused a delay in patient recruitment and probably a worse clinical course in the patients selected. The need for the initiation of treatment in the early stages of the disease should be emphasized.

Patients with IPF seemed to have good tolerance to treatment with BM-MSC via bronchoscopIc infusion. However, even though small volumes of fluid were administered, the procedure may cause symptoms in some patients and might eventually cause clinical deterioration in individuals with more severe IPF. When the study was designed, the treatment choice was the endobronchial infusion of autologous bone-marrow-derived mesenchymal stromal cells. One of the limitations of the systemic administration of MSCs cells is the inefficient homing of the cells, although it can be enhanced in the acutely injured lung (25) (24). The endobronchial infusion may overcome this issue. However, some of the patients in our study experienced symptoms after the infusion, especially those who received higher volumes of fluid.

As a general rule, the chosen site of infusion was the lower lobe of the less fibrotic lung, considering that presumably the immunomodulatory and /or regenerative effect of the MSCs could be null in an intensely fibrotic parenchyma. On the other hand, infusing cells into the less fibrotic lung might compromise more functional parenchymal areas if any local adverse effects were derived, such as inflammation, infection, or - although hardly expected - carcinogenesis.

Thus, although the patients had diffuse and quite symmetric damage in both lower lobes, for safety reasons future studies should be aware of patients with predominantly right or left fibrosis.

Previously reported clinical trial phase I used autologous adipose driven MSCs by endobronchial three infusions in 14 patients and provides some comparative data(27). Adipose-derived cells were not expanded and nor cultured. After the infusion, half of the patients experienced fever in 50% cases, and 14% some minor effects such as mild cough, dyspnea or desaturation, but not clinically severe effects in follow up to one year.

Two other clinical trials administer MSC via intravenously. One administered placenta-derived MSCs in 8 patients (28). During the MSC infusion there was a mild fall in SaO2 after 15 min (1% (range 0-2%)), but without changes in haemodynamics, which may be attributed to transient vascular obstruction due to the size of MSCs. The AETHER study administered intravenous allogeneic MSCs in 9 patients (29) and did not report any relevant adverse events during the infusion, but some patients deteriorated during long-term follow-up.

The potential advantage of using autologous cells is avoiding immune reactions, especially if the cells differentiate over time. On the other hand, allogeneic cells are easier to develop and stock, resulting in higher availability, although they tend to show less antiinflammatory response(34). In older patients or those with specific conditions, autologous cells have limited expansion due to increased cellular senescence.

In this regard, one unexpected finding in the study was that six cultures in 4 patients yielded MSCs with chromosome aberrations and that were not appropriate for treatment. In our experience, these alterations are uncommon when BM-MSC are obtained from patients with other diseases and raise the question whether bone marrow stromal cells in IPF patients have more genomic instability. An extensive analysis of chromosome aberrations in adult stromal cells reported a frequency of approximately 4% for MSCs(35), markedly lower than what we

found in our cohort. As reported by others, the recurrence of trisomy 5 in repeated samples from 3 patients suggests this is a donor-dependent phenomenon (36) (37). Features of senescence in BM-MSCs obtained in IPF patients have been previously reported(38) and may be involved in IPF pathogenesis(39). Further studies are warranted to understand the mechanisms beyond IPF, including pulmonary and bone marrow stromal cell abnormalities. Meanwhile, we conclude that autologous bone marrow might not be a good source of MSCs in IPF.

The high incidence of chromosomal alterations seen after culture in IPF patients in the present study seems to limit the use of autologous cells and favour allogeneic cells for further studies.

Other important issues not considered in this discussion are the cells' different properties depending on their processing. Finally, and due to the main paracrine effect, the use of MSCs derived products has been advocated for potential immunomodulatory therapy to explore in well-designed studies.

Limitations

Conclusions from this study cannot be easily extrapolated to current patients with IPF since most patients will be receiving new antifibrotic therapies. There might be a validation group to prove the efficacy and comparative safety of the treatment. Newer studies should be conducted in patients on currently approved pharmacologic treatments. Furthermore, half of the patients in this study did not complete the 12-month follow-up due to death (3 patients), lung transplantation (1 patient), and IPF progression precluding follow-up visits (2 patients). However, all recruited patients were followed and checked for adverse events for at least three months.

This small phase Istudy was designed to evaluate safety and is not powered to detect significant lung function changes.

Conclusions

In a group of patients with IPF, the endobronchial infusion of BM-MSCS did not directly cause serious adverse events. Acute effects of endobronchial infusion were infrequent, transient, and not serious, although this therapy might be challenging in severe patients and particularly with higher doses. Two patients developed cancer within the follow-up period, although not likely related to the treatment. At the end of the follow-up period, clinical progression of the disease or significant functional decline was high, as was observed in 8 out of 13 patients.

Finally, a relatively frequent genomic instability of MSCs is found during culture, which may preclude the use of autologous mesenchymal stromal cells in IPF patients.

Abbreviations

6MWT: 6-minute walk test

AE: adverse event

AEMPS: Spanish Agency for Medicines and Health Products

BM-MSCs: bone marrow mesenchymal stromal cells

CGH: comparative genomic hybridisation

DLCO: diffusion capacity of the lung for carbon monoxide

FVC: forced vital capacity

GMP: good manufacture

HRCT: high resolution computed tomography

IPF: idiopathic pulmonary fibrosis

MRC: Medical Research Council

MSCs: mesenchymal stromal cells

PFTs: pulmonary function tests

SGRQ: Saint George Respiratory Questionnaire

TLC: total lung capacity

Acknowledgements

We acknowledge the contribution of Elena de Miguel and Teresa Jiménez for their invaluable work in assessing our patients' respiratory function. We also acknowledge the Clínica Universidad de Navarra - Clinical Trials Unit support for their support during the implementation of the study and further analysis.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

All the data presented is available upon request.

Ethics approval and consent to participate

The Institutional Review Board of Navarra and the Spanish Agency of Medicines and Medical Devices approved all the procedures.

References

1. Zhang G-Y, Liao T, Gao W-Y. MUC5B Promoter Polymorphism and Pulmonary Fibrosis. N Engl J Med. 2011; 365(2): 178-9.

2. Armanios MY, Chen JJ-L, Cogan JD, Alder JK, Ingersoll RG, Markin C, et al. Telomerase Mutations in Families with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2007; 356(13): 1317-26.

3. Nogee L, Dunbar AE, Wert S, Askin F. A mutation in the surfactant protein c gene associated with familial interstitial lung disease. N Engl J Med. 2001; 344: 573-9.

4. Albert RK, Schwartz DA. Revealing the Secrets of Idiopathic Pulmonary Fibrosis. Phimister EG, editor. N Engl J Med. 2019;380(1):94–6.

5. Kolb M, Bonella F, Wollin L. Therapeutic targets in idiopathic pulmonary fibrosis. Respir Med. 2017; 131: 49–57.

6. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet [Internet]. 2011 May;377(9779):1760–9. Lancet. 2011; 377: 1760-9.

7. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014; 370(22):2083–92.

8. Richeldi L, Du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med 2014 ; 22:2071–82.

9. Vancheri C, Kreuter M, Richeldi L, Ryerson CJ, Valeyre D, Grutters JC, et al. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial. Am J Respir Crit Care Med. 2018; 197(3):356–63.

10. Richeldi L, Costabel U, Selman M, Soon Kim D, Hansell DM, Nicholson AG, et al. Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis. N Engl J Med 2011; 365(12): 1079-87

11. Troy LK, Corte TJ. Therapy for idiopathic pulmonary fibrosis: lessons from pooled data analyses. Eur Respir J. 2016; 47(1):27–30.

12. Ley B, Swigris J, Day B mo, Stauffer JL, Raimundo K, Chou W, et al. Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2017; 196(6):756–61.

13. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med [Internet]. 2012 May 15 [cited 2018 May 24];156(10):684–91.

14. Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5(1):33–41.

15. Wakwaya Y, Brown KK. Idiopathic Pulmonary Fibrosis: Epidemiology, Diagnosis and Outcomes. Am J Med Sci. 2019; 357(5):359–69.

16. Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis [Internet]. Vol. 183, American Journal of Respiratory and Critical Care Medicine. American Thoracic Society; 2011; 183(4): 431–40.

17. Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: Incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014; 2(7): 566–72.

18. Lee RH, Oh JY, Choi H, Bazhanov N. Therapeutic factors secreted by mesenchymal stromal cells and tissue repair. J Cell Biochem. 2011; 112(11): 3073-8.

19. Ortiz LA, DuTreil M, Fattman C, Pandey AC, Torres G, Go K, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci. 2007; 104(26): 11002-7.

20. Zhao F, Zhang YF, Liu YG, Zhou JJ, Li ZK, Wu CG, et al. Therapeutic Effects of Bone Marrow-Derived Mesenchymal Stem Cells Engraftment on Bleomycin-Induced Lung Injury in Rats. Transplant Proc. 2008; 40(5):1700–5.

21. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA. Intrapulmonary Delivery of Bone Marrow-Derived Mesenchymal Stem Cells Improves Survival and Attenuates Endotoxin-Induced Acute Lung Injury in Mice. J Immunol. 2007; 179(3):1855–63.

22. Xu J, Woods CR, Mora AL, Joodi R, Brigham KL, Iyer S, et al. Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. Am J Physiol Cell Mol Physiol. 2007; 293(1): L131-41.

23. Rojas M, Xu J, Woods CR, Mora AL, Spears W, Roman J, et al. Bone Marrow–Derived Mesenchymal Stem Cells in Repair of the Injured Lung. Am J Respir Cell Mol Biol. 2005 ; 33(2):145–52.

24. Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci. 2003; 100(14): 8407-11.

25. Von Bahr L, Batsis I, Moll G, Hägg M, Szakos A, Sundberg B, et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells. 2012; 30(7): 1575-8.

26. Mohammadipoor A, Antebi B, Batchinsky AI, Cancio LC. Therapeutic potential of products derived from mesenchymal stem/stromal cells in pulmonary disease. Respir Res 2018; 19: 218.

27. Tzouvelekis A, Paspaliaris V, Koliakos G, Ntolios P, Bouros E, Oikonomou A, et al. A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med. 2013;11: 171..

28. Chambers DC, Enever D, Ilic N, Sparks L, Whitelaw K, Ayres J, et al. A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. Respirology. 2014;19(7):1013–8.

29. Glassberg MK, Minkiewicz J, Toonkel RL, Simonet ES, Rubio GA, DiFede D, et al. Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial. Chest 2017; 151(5): 971–81.

30. Ntolios P, Manoloudi E, Tzouvelekis A, Bouros E, Steiropoulos P, Anevlavis S, et al. Longitudinal outcomes of patients enrolled in a phase Ib clinical trial of the adipose-derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. Clin Respir J. 2018; 12(6): 2084–9.

31. Heo JS, Choi Y, Kim HS, Kim HO. Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue. Int J Mol Med. 2016; 37(1):115–25.

32. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183(6):788–824.

33. Lamo-Espinosa JM, Mora G, Blanco JF, Granero-Moltó F, Nuñez-Córdoba JM, Sánchez-Echenique C, et al. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee

osteoarthritis: Multicenter randomized controlled clinical trial (phase I/II). J Transl Med. 2016 Aug 26;14(1):246.

34. Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: Environmentally responsive therapeutics for regenerative medicine. Exp Mol Med. 2013;45(11):1–16.

35. Ben-David U, Mayshar Y, Benvenisty N. Large-scale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells. Cell Stem Cell. Cell Press; 2011; 9: 97–102.

36. Tarte K, Gaillard J, Lataillade J-J, Fouillard L, Becker M, Mossafa H, et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 2010; 115(8): 1549-53.

37. Stultz BG, McGinnis K, Thompson EE, Lo Surdo JL, Bauer SR, Hursh DA. Chromosomal stability of mesenchymal stromal cells during in vitro culture. Cytotherapy. 2016; 18(3): 336–43.

38. Cárdenes N, Álvarez D, Sellarés J, Peng Y, Corey C, Wecht S, et al. Senescence of bone marrow-derived mesenchymal stem cells from patients with idiopathic pulmonary fibrosis. Stem Cell Res Ther. 2018; 9(1): 257.

39. Antoniou KM, Papadaki HA, Soufla G, Kastrinaki MC, Damianaki A, Koutala H, et al. Investigation of bone marrow mesenchymal stem cells (BM MSCs) involvement in idiopathic pulmonary fibrosis (IPF). Respir Med. 2010; 104(10): 1535–42.

Table 1. Baseline characteristics of patients

	Low dose ($10x10^6$ MSCs)	Intermediate dose ($50x10^6$ MSCs)	High dose ($100x10^6$ MSCs)	Total
Number	3	3	7	13
Age, median (IQR)	60.5 (54.4 – 68.0)	65.6 (64.3 – 78.0)	70.2 (66.1 – 78.0)	68.0 (64.3 – 77.2)
Sex (male/female)	3/ 0	3/ 0	6 / 1	12/ 1
Time since IPF symptoms (years)	4.1 ± 1.7	3.5 ± 3.7	3.0 ± 1.6	3.3 ± 2.1
Time since IPF diagnosis (years)	1.9 ± 2.1	3.5 ± 4.0	1.6 ± 1.7	2.1 ± 2.4
Current or former smoker	3 (100%)	2 (66.67%)	5 (71.43%)	10 (76.9%)
Pack-years	19.7 ± 4.5	20.0 ± 0	22.5 ± 22.1	21.0 ± 13.8
BMI, kg/m^2	27.7 ± 1.9	29.4 ± 1.0	26.3 ± 2.7	27.4 ± 2.5
Baseline SpO2	96.0 ± 2.6	94.7 ± 0.6	95.3 ± 1.6	95.3 ± 1.7
Dyspnoea (MRC scale) 0-1-2-3	1-1-0-1	1-2-0-0	0-6-1-0	2-9-1-1
Cough intensity (0-3)	0-0-2-1	0-1-2-0	1-3-1-2	1-4-5-3
Cough frequency, median (IQR)	5 (5-7)	3 (2-4)	3 (2-4)	3 (2-5)
SGRQ symptoms	39.4 (23.8 – 50.7)	21.2 (0 – 39.0)	30.5 (23.8 – 36.9)	30.5 (23.8 – 39.0)
SGRQ activity	67.2 (0 – 73.0)	67.1 (35.5 – 73.8)	48.3 (41.5 – 67.1)	48.5 (41.5 – 67.2)
SGRQ impact	49.7 (0 – 50.1)	24.1 (11.6 – 36.0)	15.3 (10.3 – 30.6)	16.0 (11.6 – 36.0)
SGRQ total	53.3 (4.0 – 57.1)	37.8 (20.5 – 49.0)	24.2 (23.2 – 44.1)	28.9 (23.2 – 49.0)
Baseline PaO2, mmHg	76.7 ± 14.2	72.7 ± 4.7	68.0 ± 4.1	71.3 ± 7.9
FVC (% predicted)	83.7 ± 36.5	69.4 ± 15.6	74.9 ± 15.8	75.6 ± 20.3
FEV1 (% predicted)	82.3 ± 33.3	75.2 ± 12.0	77.1 ± 16.7	77.9 ± 18.9
FEV1/FVC, %	78.7 ± 2.1	84.0 ± 7.5	80.1 ± 7.3	80.7 ± 6.4
TLC (% predicted)	66.0 ± 25.2	58.5 ± 9.0	60.9 ± 9.8	61.5 ± 13.2

DLCO adj (% predicted)	45.7 ± 18.5	57.0 ± 18.7	43.1 ± 5.7	46.9 ± 12.9
6MWT distance, m	476.0 ± 114.5	491.0 ± 56.7	491.9 ± 63.6	488 ± 69.2
6MWT SpO2 nadir	87.0 ± 8.9	88.0 ± 1.7	77.9 ± 6.8	82.3 ± 7.9
HRCT findings:				
- Traction bronchiectasis	3	3	6	12
- Reticular pattern	3	3	7	13
- Honeycombing	1	2	7	10
Pulmonary biopsy	2 (66.67%)	2 (100%)	1 (14.29%)	5 (38.5%)

Table 2. Adverse events and outcomes.

Adverse events	MedDRA Code	Number of patients	Severity (mild/moderate/severe/life-threatening)	Seriousness (non serious/ serious)	First 3 months after infusion	Outcome at 12 months
Bronchitis	10006451	8 (61.5%)	8/0/0/0	8/0	5	Resolved
IPF clinical progression or worsening without hospitalisation	10067761	5 (38.5%)	0/3/2/0	5/0	1	4 IPF progression 1 Lung transplant
IPF worsening with hospitalisation (2 patients)	10067761 10054112	3 (23.1%)*	0/2/1/0	0/3	1	1 death
Fever and/or dyspnoea after infusion	10013968 10037660	3 (23.1%)	1/2/0/0	3/0	3	Resolved
Upper respiratory tract infection/ sinusitis	10046309	2 (15.4%)	2/0/0/0	2/0	2	Resolved
Flu-like syndrome	10022004	2 (15.4%)	2/0/0/0	2/0	6	Resolved
Acute gastroenteritis	10066762	1 (7.7%)	1/0/0/0	1/0	1	Resolved
Skin lesion	10040882	1 (7.7%)	1/0/0/0	1/0	1	Resolved
Legionella pneumonia with hospitalisation	10035718	1 (7.7%)	0/0/0/1	0/1	0	1 death
Abdominal pain, weight decreased, and general deterioration	10000081 10000159 10049438	1 (7.7%)	0/1/0/0	1/0	1	1 death
Prostate adenocarcinoma	10060862	1 (7.7%)	0/1/0/0	0/1	0	On treatment
Small cell lung cancer	10041067	1 (7.7%)	1/0/0/0	0/1	0	On treatment
Radiotherapy side effects with hospitalisation (prostate cancer treatment)	10037759	1 (7.7%)	0/1/0/0	1/0	0	Resolved

- One patient was hospitalised twice during a 2 months period.

Table 3. Changes in pulmonary function, 6 MWT, and quality of life.

	Time after infusion					
	1 month	2 months	3 months	6 months	9 months	12 months
n	13	11	13	10	7	6
ΔFVC, mL (SD)	-93 (240)	-184 (272)*	-212 (275)*	-200 (240)*	-214 (292)	-212 (189)*
ΔFVC %change (SD)	-3.7 (10.8)	-6.8 (12.7)	-8.1 (11.7)	-7.7 (10.5)	-7.0 (10.5)	-7.6 (6.4)
ΔTLC mL (SD)	27 (267)	-79 (187)	-151 (315)	-169 (370)	-260 (338)	-345 (374)
ΔTLC %change (SD)	0.5 (4.1)	-1.3 (2.9)	-2.3 (4.9)	-2.7 (5.9)	-4.3 (5.0)	-5.5 (5.5)
ΔDLCO mL/mmHg/min	-0.2 (1.3)	-0.2 (1.7)	-1.1 (1.7)*	-0.9 (1.9)	-1.2 (2.3) (n = 6)	-1.5 (2.6)
ΔDLCO% (SD)	-1.7 (11.1)	-2.6 (11.6)	-9.5 (14.2)	-8.3 (14.3)	-12.1 (16.8) n = 6	-11.5 (19.5)
Δ6MWT distance, m	5.3 (32.4)	9.0 (34.6)	1.8 (71.4)	-9.8 (37.3)	-40.0 (83.1)	-16.7 (41.3)
Patients with FVC decline <10%	11	7	7	6	4	4
Patients with DLCO decline <15%	12	10	8	7	2	4
ΔSGRQ symptoms (SD)	6.0 (14.3)	4.9 (16.6)	5.6 (19.9)	3.1 (16.4)	10.8 (30.8)	3.6 (27.6)
ΔSGRQ activity (SD)	3.7 (16.7)	-1.4 (20.2)	-0.8 (23.2)	-3.8 (27.1)	7.0 (27.9)	3.8 (28.6)
ΔSGRQ impact (SD)	-0.5 (11.3)	-0.7 (10.8)	0 (16.0)	1.6 (13.0)	6.0 (20.8)	-2.9 (15.3)
ΔSGRQ total (SD)	0.7 (11.2)	-0.8 (12.6)	-0.5 (16.2)	-0.5 (15.7)	5.2 (19.8)	-2.0 (17.6)

* Significant change compared to baseline values: $p < 0.05$

Table 4. Individual baseline and functional outcomes at the end of follow-up.

ID	Dose (N of cells)	Baseline %FVC	Baseline %DLCO	Functional outcome at 3 months	Last visit	Overall outcome at last visit/ or follow-up contact	Observations: Death/ Lung transplant (LTx)*
01_01	10×10^6	53%	35%	Progression	6 months	Progression	
01_03	10×10^6	74%	35%	Stable	3 months	Other	LTx at 6 months
01_05	10×10^6	124%	67%	Stable	12 months	Stable	
01_06	50×10^6	57%	42%	Stable	9 months	Progression	
01_07	50×10^6	87%	78%	Progression	12 months	Stable	
02_01	50×10^6	64%	51%	Progression	12 months	Progression	
01_09	100×10^6	73%	42%	Progression	3 months	Other	Death at 5 months
01_10	100×10^6	61%	35%	Stable	9 months	Progression	
01_11	100×10^6	96%	53%	Stable	12 months	Stable	
01_13	100×10^6	90%	47%	Progression	12 months	Progression	
01_14	100×10^6	52%	39%	Stable	6 months	Other	Death at 8 months
01_15	100×10^6	69%	43%	Progression	3 months	Other	Death at 9 months
01_17	100×10^6	83%	43%	Progression	12 months	Progression	

Functional outcome: Progression defined by fall in FVC>=10% and/or fall in DLCO>=15%; otherwise considered stable.

***Causes of death: 01_09 *Legionella* pneumonia; 01_14 IPF progression; 01_15 Not determined.**

Figure 1. Study flow diagram for treatment.







Figure 2. Individual changes in FVC and DLCO during follow-up.